Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-054497
Filing Date
2024-05-07
Accepted
2024-05-07 16:13:00
Documents
69
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q algs-20240331.htm   iXBRL 10-Q 2070491
2 EX-31.1 algs-ex31_1.htm EX-31.1 15979
3 EX-31.2 algs-ex31_2.htm EX-31.2 15966
4 EX-32.1 algs-ex32_1.htm EX-32.1 8928
5 EX-32.2 algs-ex32_2.htm EX-32.2 8912
  Complete submission text file 0000950170-24-054497.txt   7563312

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT algs-20240331.xsd EX-101.SCH 1299274
73 EXTRACTED XBRL INSTANCE DOCUMENT algs-20240331_htm.xml XML 1058316
Mailing Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address ONE CORPORATE DR., 2ND FLOOR SOUTH SAN FRANCISCO CA 94080 (800) 466-6059
Aligos Therapeutics, Inc. (Filer) CIK: 0001799448 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39617 | Film No.: 24921997
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)